NCT04433234View on ClinicalTrials.gov

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

DS-5141b

Administered via subcutaneous injection once weekly

Trial Locations (2)

187-8551

National Center of Neurology and Psychiatry, Tokyo

650-0017

Kobe University Hospital, Hyōgo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY